Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AX-158 in Healthy Male Volunteers
NCT05218434Phase 1Completed
- Sponsor
- Artax Biopharma
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AX-158 in autoimmune diseases (12 arms), sponsored by Artax Biopharma. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events up to 10 days. Started Nov 2021; status: completed.
02
Drugs
AX-158
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT05218434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218434.